Therapeutic efficacy of Trifolium pratense L. on letrozole induced polycystic ovary syndrome in rats
DOI:
https://doi.org/10.14719/pst.2020.7.3.845Keywords:
Red clover, Endocrine disorders, Clomiphene, Antioxidant, InflammationAbstract
Polycystic ovary syndrome (PCOS) is considered as one of the leading endocrine disorders during reproductive age in women. This study designed to determine the therapeutic effects of red clover (Trifolium pratense) on letrozole-induced PCOS in vivo. Forty female Sprague–Dawley rats were equally divided into five groups. Control group with a regular sexual cycle received normal saline (letrozole vehicle). Letrozole (1 mg/kg) was used to induce the PCOS to the rats in the treatment groups. After induction of PCOS, four treatment groups received the normal saline, or clomiphene citrate (1 mg/kg), or red clover extracts (500 or 750 mg/kg) for 30-days. After treatment, ovary and uterus were removed, weighed, and the ovaries were subjected to histopathological studies. Serum testosterone and estradiol levels, antioxidant activities, and lipid profiles were evaluated. Red clover extracts and clomiphene citrate decreased testosterone levels and showed a significant increase in estradiol levels in comparison to PCOS induced group (p<0.05). Red clover administration restored the GSH, SOD and CAT levels (p<0.05) and decreased the NO and MDA levels (p<0.05). Treatments caused no significant change in levels of TG, TC, and FBG factors when compared to PCOS induced group (P>0.05). However, red clover (750 mg/kg) significantly increased HDL and decreased LDL levels when compared to PCOS induced group (P<0.05). Treatment with red clover reduced ovarian weight, volumes of ovarian, medulla, cortex and number of cysts and increased number of oocytes compared to PCOS group. Both red clover and clomiphene citrate could treat the letrozole induced PCOS in rats; however, red clover indicated antioxidant activities more than clomiphene citrate. Red clover may be used for discovering anti-PCOS drugs with lower side effects.
Downloads
References
Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metabol. 2004;89(6):2745-9. https://doi.org/10.1210/jc.2003-032046
Brutocao C, Zaiem F, Alsawas M, Morrow AS, Murad MH, Javed A. Psychiatric disorders in women with polycystic ovary syndrome: a systematic review and meta-analysis. Endocrine. 2018;62:318–25. https://doi.org/10.1007/s12020-018-1692-3
DuRant EM, Leslie NS, Critch EA. Managing polycystic ovary syndrome: a cognitive behavioral strategy. Nurs women's health. 2009;13(4):292-300. https://doi.org/10.1111/j.1751-486X.2009.01439.x
Walters K, Bertoldo M, Handelsman D. Evidence from animal models on the pathogenesis of PCOS. Best Prac Res Clin Endocrinol Metabol. 2018;32(3):271-81. https://doi.org/ 10.1016/j.beem.2018.03.008
Hartmann G, McEwen B. Insulin resistance and Polycystic ovary syndrome (PCOS): Part 2. Diet and Nutritional Medicine. J Australian Trad Med Soc. 2019;25(1):18.
Yilmaz B, Vellanki P, Ata B, Yildiz BO. Metabolic syndrome, hypertension, and hyperlipidemia in mothers, fathers, sisters, and brothers of women with polycystic ovary syndrome: a systematic review and meta-analysis. Fertil Steril. 2018;109(2):356-64.e32.https://doi.org/ 10.1016/j.fertnstert.2017.10.018
Khan Z, Khan R, Bukhari AS, Ahmad W. Comparative effectiveness of ovulation induction therapy in women with polycystic ovarian syndrome. J Soc Obstet Gynaecol Pak. 2017;7(3):128-32.
Tanbo T, Mellembakken J, Bjercke S, Ring E, Åbyholm T, Fedorcsak P. Ovulation induction in polycystic ovary syndrome. Acta Obstet Gynecol Scand. 2018;97(10):1162-7. https://doi.org/ 10.1111/aogs.13395
Legro RS. Ovulation induction in polycystic ovary syndrome: current options. Best Prac Res Clin Obstet Gynaecol. 2016;37:152-9. https://doi.org/10.1016/j.bpobgyn.2016.08.001
Evans A, Hoeger KM. PCOS in adolescence: Towards a better diagnosis and treatment. Curr Opinion Endoc Metabol Res. 2020;12;105-11. https://doi.org/10.1016/j.coemr.2020.04.010
Kooti W, Ahangarpoor A, Ghasemiboroon M, Sadeghnezhadi S, Abbasi Z, Shanaki Z, et al. Effect of Apium graveolens leaf extract on serum level of thyroid hormones in male rat. J Babol Univ Med Sci. 2014;16(11):44-50
Heidari-Soreshjani S, Asadi-Samani M, Yang Q, Saeedi-Boroujeni A. Phytotherapy of nephrotoxicity-induced by cancer drugs: An updated review. J Nephropathol. 2017;6(3):254-63. https://doi.org/10.15171/jnp.2017.41
Parsaei P, Bahmani M, Naghdi N, Asadi-Samani M, Rafieian-Kopaei M. A review of therapeutic and pharmacological effects of thymol. Der Pharm Lett. 2016;8(2):150-4
Vlaisavljevic S, Kaurinovic B, Popovic M, Djurendic-Brenesel M, Vasiljevic B, Cvetkovic D, et al. Trifolium pratense L. as a potential natural antioxidant. Molecules. 2014;19(1):713-25. https://doi.org/ 10.3390/molecules19010713
Zhang H, Zhao J, Shang H, Guo Y, Chen S. Extraction, purification, hypoglycemic and antioxidant activities of red clover (Trifolium pratense L.) polysaccharides. Int J Biol Macromol. 2020;148:750-60. https://doi.org/10.1016/j.ijbiomac.2020.01.194
Khazaei M, Pazhouhi M, Khazaei S. Evaluation of hydro-alcoholic extract of Trifolium Pratense L. for its anti-cancer potential on U87MG Cell line. Cell J. 2018;20(3):412. https://doi.org/10.22074/cellj.2018.5380
Krenn L, Unterrieder I, Ruprechter R. Quantification of isoflavones in red clover by high-performance liquid chromatography. J Chromatogr B. 2002;777(1-2):123-8. https://doi.org/10.1016/s1570-0232(02)00079-x.
Kanadys W, Baranska A, Jedrych M, Religioni U, Janiszewska M. Effects of red clover (Trifolium pratense) isoflavones on the lipid profile of perimenopausal and postmenopausal women—A systematic review and meta-analysis. Maturitas. 2020;132:7-16. https://doi.org/10.1016/j.maturitas.2019.11.001
Fritz H, Seely D, Flower G, Skidmore B, Fernandes R, Vadeboncoeur S, et al. Soy, red clover, and isoflavones and breast cancer: a systematic review. Plos One. 2013;8(11):e81968. https://doi.org/10.1371/journal.pone.0081968
Rezvanfar M, Ahmadi A, Shojaei-Saadi H, Baeeri M, Abdollahi M. Molecular mechanisms of a novel selenium-based complementary medicine which confers protection against hyperandrogenism-induced polycystic ovary. Theriogenology. 2012;78(3):620-31. https://doi.org/10.1016/j.theriogenology.2012.03.008
Osuka S, Nakanishi N, Murase T, Nakamura T, Goto M, Iwase A, et al. Animal models of polycystic ovary syndrome: A review of hormone induced rodent models focused on hypothalamus pituitary ovary axis and neuropeptides. Reprod Med Biol. 2019;18(2):151-60. https://doi.org/10.1002/rmb2.12262
Reddy PS, Begum N, Mutha S, Bakshi V. Beneficial effect of curcumin in letrozole induced polycystic ovary syndrome. Asian Pac J Reprod. 2016;5(2):116-22. https://doi.org/ 10.1016/j.apjr.2016.01.006
Kakkar P, Das B, Viswanathan PN. A modified spectrophotometric assay of superoxide dismutase. Indian J Biochem Biophys. 1984;21(2):130-2
Beers RF, Sizer IW. A spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase. J Biol Chem. 1952;195(1):133-40
Jollow DJ, Mitchell JR, Zampaglione N, Gillette JR. Bromobenzene-induced liver necrosis. Protective role of glutathione and evidence for 3,4-bromobenzene oxide as the hepatotoxic metabolite. Pharmacology. 1974;11(3):151-69
Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Analytical biochemistry. 1979;95(2):351-8
Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Anal Biochem. 1982;126(1):131-8
Karbalay-Doust S, Noorafshan A. Stereological estimation of ovarian oocyte volume, surface area and number: application on mice treated with nandrolone decanoate. Folia Histochem Cytobiol. 2012;50:275–279.https://doi.org/ 10.5603/fhc.2012.0037
Caldwell ASL. Unravelling the role of androgens in polycystic ovary syndrome. PhD [dissertation]. ANZAC Research Institute: The University of Sydney; 2018. Available from http://hdl.handle.net/2123/18129
Huang J, Ding Y, Li Z. The regulation of the follicular synchronization and sensitivity of rats with PCOS by AMH during prolonged pituitary downregulation. Gene. 2019;721:144106. https://doi.org/10.1016/j.gene.2019.144106
Shabbir S, Naz L, Khan Z, Memon AA. Beneficial effects of Prunus dulcis (almond oil) on letrozole-induced polycystic ovarian syndrome in rats. Int J Pure App Biosci. 2019;7(3):1-14. https://doi.org/10.1016/j.jtumed.2020.02.002
Weber K, Setchell K, Stocco D, Lephart E. Dietary soy-phytoestrogens decrease testosterone levels and prostate weight without altering LH, prostate 5alpha-reductase or testicular steroidogenic acute regulatory peptide levels in adult male Sprague-Dawley rats. J Endocrinol. 2001;170(3):591-9. https://doi.org/10.1677/joe.0.1700591
Zilaee M, Mansoori A, Ahmad HS, Mohaghegh SM, Asadi M, Hormoznejad R. The effects of soy isoflavones on total testosterone and follicle-stimulating hormone levels in women with polycystic ovary syndrome: a systematic review and meta-analysis. Eur J Contracept Reprod Health Care. 2020:1-6. https://doi.org/10.1080/13625187.2020.1761956
Zhang T, Chi X. Estrogenic properties of genistein acting on FSHR and LHR in rats with PCOS. Pol J Vet Sci. 2019;22(1):83-90. https://doi.org/ 10.24425/pjvs.2019.127075
Rajaei S, Alihemmati A, Abedelahi A. Antioxidant effect of genistein on ovarian tissue morphology, oxidant and antioxidant activity in rats with induced polycystic ovary syndrome. Int J Reprod BioMed. 2019;17(1):11-22. https://dx.doi.org/10.18502%2Fijrm.v17i1.3816
Beck V, Rohr U, Jungbauer A. Phytoestrogens derived from red clover: an alternative to estrogen replacement therapy? J Steroid Biochem Mol Biol. 2005;94(5):499-518. https://doi.org/10.1016/j.jsbmb.2004.12.038
Bannigida DM, Nayak SB. Coronary risk factors and oxidative stress in women with PCOS. Indian J Med Biochem. 2019;23(2):268. https://doi.org/ 10.5005/jp-journals-10054-0101
Santoso B, Zuhri AS, Alkaff FF. Hyperbaric oxygen therapy effect on androgen receptor and superoxide dismutase in insulin-resistant polycystic ovary syndrome. J Int Dental Med Res. 2020;13(1):144-8
Mostafa M, Ferdousi S, Sultana S, Akhter A. Autonomic impairment and oxidative stress: Relationship in PCOS patients. J Bangladesh Soc Physiol. 2019;14(2):82-8
Plenchette S, Paul C, Bettaieb A. Nitric oxide and platinum-derivative-based regimens for cancer treatment: from preclinical studies to clinical trials. Nitric Oxide (Donor/Induced) in Chemosensitizing: Elsevier; 2017. p. 91-103
Kashfi K, Duvalsaint PL. Nitric oxide donors and therapeutic applications in cancer. Nitric Oxide Donors: Elsevier; 2017. p. 75-119
Savi?-Radojevi? A, Mažibrada I, Djuki? T, Stankovi? ZB, Plješa-Ercegovac M, Sedlecky K, et al. Glutathione S-transferase (GST) polymorphism could be an early marker in the development of polycystic ovary syndrome (PCOS)—an insight from non-obese and non-insulin resistant adolescents. Endokrynol Pol. 2018;69(4):366-74. https://doi.org/ 10.5603/EP.a2018.0034
Sulaiman MA, Al-Farsi YM, Al-Khaduri MM, Saleh J, Waly MI. Polycystic ovarian syndrome is linked to increased oxidative stress in Omani women. Int J Women Health. 2018;10:763. https://doi.org/ 10.2147/IJWH.S166461
Deligeoroglou E, Vrachnis N, Athanasopoulos N, Iliodromiti Z, Sifakis S, Iliodromiti S, et al. Mediators of chronic inflammation in polycystic ovarian syndrome. Gynecol Endocrinol. 2012;28(12):974-8. https://doi.org/10.3109/09513590.2012.683082
Fatima Q, Amin S, Kawa IA, Jeelani H, Manzoor S, Rizvi SM, et al. Evaluation of antioxidant defense markers in relation to hormonal and insulin parameters in women with polycystic ovary syndrome (PCOS): A case-control study. Diabet Metab Syndr. 2019;13(3):1957-61. https://doi.org/ 10.1016/j.dsx.2019.04.032
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Zahra Abbasian, M Jafari Barmak, Fatemeh Barazesh, M Ghavamizadeh, Ali Mirzaei
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright and Licence details of published articles
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Open Access Policy
Plant Science Today is an open access journal. There is no registration required to read any article. All published articles are distributed under the terms of the Creative Commons Attribution License (CC Attribution 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited (https://creativecommons.org/licenses/by/4.0/). Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
